![]() |
|
|
Vol. 287, Issue 1, 266-283, October 1998
Centre de Recherche Pierre Fabre, Castres Cedex, France
F 11440 (4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H,4H-1,2,4-triazin-3,5-dione)
was the outcome of a research effort guided by the hypothesis that the
magnitude of the intrinsic activity of agonists at 5-HT1A
receptors determines the magnitude of their antidepressant and
anxiolytic-like effects. The affinity of F 11440 for 5-HT1A
binding sites (pKi, 8.33) was higher than
that of buspirone (pKi, 7.50), and somewhat
lower than that of flesinoxan (pKi, 8.91).
In vivo, F 11440 was 4- to 20-fold more potent than
flesinoxan, and 30- to 60-fold more potent than buspirone, in exerting
5-HT1A agonist activity at pre- and postsynaptic receptors
in rats (measured by, for example, its ability to decrease hippocampal
extracellular serotonin (5-HT) levels and to increase plasma
corticosterone levels, respectively). F 11440 did not have detectable
antidopaminergic activity (unlike buspirone, which inhibited all of the
directly observable behavioral effects of methylphenidate in rats),
showed no evidence of antihistaminergic activity (unlike flesinoxan,
which protected against the effects of a histamine aerosol in guinea
pigs), and had a 70-fold separation between its 5-HT1A
agonist and alpha-1 adrenergic antagonist properties (measured as the ability to inhibit the methoxamineinduced
increase in blood pressure in rats), unlike flesinoxan, which showed a <3-fold separation. In HeLa cells expressing human 5-HT1A
receptors, F 11440 decreased the forskolin-induced increase in AMP,
and, based on its maximal effect, was found to have an intrinsic
activity of 1.0 relative to that of 5-HT, which was significantly
higher than that of buspirone (0.49), ipsapirone (0.46) and flesinoxan (0.93). Consistent with the aforementioned hypothesis, F 11440 produced
anxiolytic- and antidepressant-like effects in animal models
(i.e., increased punished responding in a pigeon
conflict procedure and decreased immobility in a rat forced swimming
test, respectively) that were more substantial than those of buspirone, ipsapirone and flesinoxan. Thus, F 11440, shown here to be a potent, selective, high efficacy 5-HT1A receptor agonist, appears
to have the potential to exert marked anxiolytic and antidepressant
activity in humans.
This article has been cited by other articles:
![]() |
S. J. Wilson, J. E. Bailey, A. S. Rich, J. Nash, M. Adrover, A. Tournoux, and D. J. Nutt The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans J Psychopharmacol, November 1, 2005; 19(6): 609 - 613. [Abstract] [PDF] |
||||
![]() |
P. J. Pauwels and F. C. Colpaert Ca2+ Responses in Chinese Hamster Ovary-K1 Cells Demonstrate an Atypical Pattern of Ligand-Induced 5-HT1A Receptor Activation J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 608 - 614. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. P. J. M. Spooren, A. Vassout, H. C. Neijt, R. Kuhn, F. Gasparini, S. Roux, R. D. Porsolt, and C. Gentsch Anxiolytic-Like Effects of the Prototypical Metabotropic Glutamate Receptor 5 Antagonist 2-Methyl-6-(phenylethynyl)pyridine in Rodents J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1267 - 1275. [Abstract] [Full Text] |
||||